SCHEMBL3787407

SCHEMBL3787407

O=C(O)c1cnc2ccncc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.64
NAPRT Q6XQN6 1/20 0.45
HCAR2 Q8TDS4 5/20 0.44
ALDH1A1 P00352 3/20 0.44
APP P05067 1/20 0.44
GAA P10253 1/20 0.44
HCAR3 P49019 1/20 0.44
PSMD14 O00487 1/20 0.44
CSNK2A2 P19784 2/20 0.41
CSNK2B P67870 2/20 0.41
P4HA1 P13674 3/20 0.41
P4HTM Q9NXG6 2/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
MIF P14174 1/20 0.40
KMO O15229 1/20 0.40
CFTR P13569 1/20 0.40
KDM4E B2RXH2 1/20 0.39
KDM6B O15054 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3788261 0.86 MGAM (0.64) MGAMNAPRTHCAR2ALDH1A1APP
Isoquinoline SCHEMBL28152444 0.84 MGAM (0.77) MGAMALDH1A1PSMD14MRGPRX4NPC1
SCHEMBL5314248 0.84 HPGDS (0.51) MGAMALDH1A1PSMD14CSNK2A2CSNK2B
SCHEMBL29598071 0.80 ALOX15 (0.54) ALDH1A1GAAPSMD14CSNK2A2CSNK2B
SCHEMBL12076107 0.80 ALOX15 (0.54) ALDH1A1GAAPSMD14CSNK2A2CSNK2B
SCHEMBL10465639 0.79 MGAM (0.70) MGAMNAPRTALDH1A1GAAPSMD14
SCHEMBL529465 0.79 MAP4K4 (0.63) MGAMNAPRTCSNK2A2CSNK2B
SCHEMBL29362407 0.78 MGAM (1.00) MGAMALDH1A1PSMD14NPC1RAB9A
SCHEMBL28048 0.78 MGAM (1.00) MGAMALDH1A1PSMD14NPC1RAB9A
SCHEMBL21945258 0.77 MAOB (0.53) ALDH1A1NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
EP-4541794-A1 PHENYL-SUBSTITUTED DIHYDRONAPHTHYRIDINE COMPOUNDS, AND PREPARATION AND USE THEREOF Suzhong Pharmaceutical Group Co., Ltd. (CN) 2025-04-23 EP disclosed
CN-119585263-A Phenyl substituted dihydro Cai compounds and preparation and application thereof 苏中药业集团股份有限公司 2025-03-07 CN disclosed
WO-2025011008-A1 PHARMACEUTICAL PREPARATION CONTAINING PHENYL-SUBSTITUTED DIHYDRONAPHTHYRIDINE COMPOUND, AND USE THEREOF 苏中药业集团股份有限公司 2025-01-16 WO disclosed
CN-119306715-A Crystal of phenyl substituted dihydronaphthyridine compound and application thereof 苏中药业集团股份有限公司 2025-01-14 CN disclosed
CN-119302952-A Pharmaceutical preparation containing phenyl substituted dihydronaphthyridine compound and application thereof 苏中药业集团股份有限公司 2025-01-14 CN disclosed
CN-118696036-A PARP1 inhibitors 突触活化疗法股份有限公司 2024-09-24 CN disclosed
US-12024518-B1 Pyrazolo[4,3-C][1,6]naphthyridines as CK2 inhibitors King Faisal University (SA) 2024-07-02 US disclosed
WO-2024022481-A1 PHENYL-SUBSTITUTED DIHYDRONAPHTHYRIDINE COMPOUNDS, AND PREPARATION AND USE THEREOF 苏中药业集团股份有限公司 2024-02-01 WO disclosed
WO-2021032687-A1 ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES UCB Biopharma SRL (BE) 2021-02-25 WO disclosed
US-20200123152-A1 Chemical Compounds as H-PGDS Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-04-23 US disclosed
US-20200123152-A1 Chemical Compounds as H-PGDS Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-04-23 US disclosed
WO-2020065613-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 WO disclosed
US-20200102303-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 US disclosed
CN-110753692-A Chemical compounds as H-PGDS inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2020-02-04 CN disclosed
CN-105612158-B The somatostatin receptor hypotype 5 (SSTR5) antagonist 武田药品工业株式会社 2017-06-30 CN disclosed
WO-2010112826-A2 HERBICIDAL COMPOUNDS SYNGENTA LIMITED (GB) 2010-10-07 WO disclosed
US-5039679-A Cardiovascular disorders GOEDECKE AKTIENGESELLSCHAFT (DE) 1991-08-13 US disclosed
US-5037987-A Production of optical isomers of certain 1,6-naphthyridine-3-carboxylate derivatives GOEDECKE AKTIENGESELLSCHAFT (DE) 1991-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123152-A1 Chemical Compounds as H-PGDS Inhibitors HPGDS, PTGS1, PTGIS MGAM 3026/4885NAPRT 2240/4885HCAR2 453/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH MGAM 863/4885NAPRT 3732/4885HCAR2 702/4885
US-20200102303-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP MGAM 163/4885NAPRT 3147/4885HCAR2 1119/4885
US-12024518-B1 Pyrazolo[4,3-C][1,6]naphthyridines as CK2 inhibitors CSNK2A3, CSNK1A1, CSNK1G3 MGAM 4357/4885NAPRT 1428/4885HCAR2 3904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.